FRAGMENT 176-191 5mg

Fragment 176-191 is a synthetic peptide analog of the human growth hormone (hGH). It has a molecular weight of 1812 g/mol. The peptide consists of 16 amino acids spanning positions 176 to 191 from the C-terminus of hGH. There is also a substitution of tyrosine to phenylalanine at position 191, which is noted as a key difference from the endogenous hormone. This change enhances the peptide’s ability to break down lipids.¹ Functionally, fragment 176-191 is similar to the endogenous growth hormone-release hormone (GHRH), also known as growth hormone-releasing factor (GHRF).² GHRH binds to receptors in the pituitary gland to stimulate the release of growth hormone. Due to the amino acid substitution in the peptide, In vitro studies fragment 176-191 has shown its ability to promote fat loss. As a result, it is often referred to as the “lipolytic fragment.” Studies in mice have confirmed these findings. In a mouse model genetically engineered to have larger fat stores, fragment 176-191 was found to enhance fat loss. To confirm the mechanism, researchers then treated mice with a genetic knockout of the beta-3 adrenergic receptor (ADRB3) — these animals did not experience fat loss when treated with fragment 176-191.³ This makes fragment 176-191 a potentially attractive method for treating obesity in the future. Additionally, the peptide has been studied as a potential diabetes therapy, as it plays a role in regulating blood sugar levels. Animal models show that fragment 176-191 gradually increases insulin levels to lower blood sugar.⁴ Fragment 176-191 does not appear to affect insulin-like growth factor 1 (IGF-1) levels, nor does it affect carbohydrate metabolism, unlike hGH.⁵ Further vitro studies are needed to confirm the role of fragment 176-191 in these conditions.

Blue Sky Peptide’s Fragment 176-191 is available as a white lyophilized powder at a concentration of 5 mg/vial. Fragment 176-191 is intended for in vitro scientific research.

References: 1. Habibullah MM, Mohan S, Syed NK, et al. Human growth hormone fragment 176-191 peptide enhances the toxicity of doxorubicin-loaded chitosan nanoparticles against MCF-7 breast cancer cells. Drug Des Devel Ther. 2022;16:1963-1974. 2. Harvey S, Martinez-Moreno CG. Growth hormone: Therapeutic possibilities—an overview. Int J Mol Sci. 2018;19(7):2015. 3. Heffernan M, Summers RJ, Thorburn A, et al. The effects of human GH and its lypolytic fragment (AOD9604) on lipid metabolim following chronic treatment in obese mice and β₃-AR knock-out mice. Endocrinology. 2001;142(12):5182-5189. 4. Ng FM, Bornstein J. Hyperglycemic action of synthetic C-terminal fragments of human growth hormone. Am J Physiol. 1978;234(5):E521-526. 5. Stier H, Vos E, Kenley D. Safety and tolerability of the hexadecapeptide AOD9604 in humans. J Endocrinol Metab. 2013;3(1-2):7-15.